PACLITAXEL News

PACLITAXEL currently has 8 news articles, with 47 predicted indications.

This page combines the AI-predicted indications for PACLITAXEL with the latest health news. Indications highlighted in orange have recent news coverage.

Drug Information

Evidence level: L5
Predicted indications (47):
- desmoplastic small round cell tumor (99.0%)
- hereditary site-specific ovarian cancer syndrome (99.0%)
- familial ovarian cancer (99.0%)
- non-small cell lung carcinoma (disease) (99.0%)
- primary peritoneal serous/papillary carcinoma (99.0%)
- breast carcinoma (99.0%)
- maligant granulosa cell tumor of ovary (99.0%)
- malignant non-dysgerminomatous germ cell tumor of ovary (99.0%)
- peritoneum cancer (99.0%)
- breast neoplasm (99.0%)
- hypertension (99.0%)
- malignant Sertoli-Leydig cell tumor of ovary (99.0%)
- borderline epithelial tumor of ovary (99.0%)
- ovarian clear cell adenocarcinoma (99.0%)
- hypertensive disorder (99.0%)
- malignant germ cell tumor of ovary (99.0%)
- ovarian mucinous adenocarcinoma (99.0%)
- yolk sac tumor (99.0%)
- primary peritoneal carcinoma (disease) (99.0%)
- open-angle glaucoma (99.0%)
- ovarian adenocarcinoma (99.0%)
- immature ovarian teratoma (99.0%)
- ovarian endometrioid adenocarcinoma (99.0%)
- ovarian small cell carcinoma (99.0%)
- ocular hypertension (99.0%)
- Kaposi's sarcoma (disease) (99.0%)
- fallopian tube cancer (99.0%)
- primary non-gestational choriocarcinoma of ovary (99.0%)
- fallopian tube carcinoma (99.0%)
- ovarian cancer (99.0%)📰 ovarian cancer
- theca steroid-producing cell malignant tumor of ovary, not further specified (99.0%)
- primary malignant peritoneal tumor (99.0%)
- hereditary breast ovarian cancer syndrome (99.0%)
- malignant dysgerminomatous germ cell tumor of ovary (99.0%)
- lung cancer (99.0%)
- malignant sex cord stromal tumor of ovary (99.0%)
- ovarian carcinosarcoma (99.0%)
- female breast carcinoma (100.0%)
- estrogen-receptor negative breast cancer (99.9%)
- hormone-resistant breast carcinoma (99.9%)
- estrogen-receptor positive breast cancer (99.9%)
- Ehrlich tumor carcinoma (99.9%)
- bilateral breast carcinoma (99.9%)
- breast carcinoma by gene expression profile (99.9%)
- nipple carcinoma (99.9%)
- parameningeal embryonal rhabdomyosarcoma (99.7%)
- botryoid-type embryonal rhabdomyosarcoma of the vagina (99.7%)